SDC1 and triple-negative breast carcinoma: Therefore, we suppressed Sdc-1 expression using siRNA knockdown (KD) in the triple-negative breast cancer cell line MDA-MB-231 to assess its effect on the TF pathway in conjunction with various cytokine treatments, referring to the role of Sdc-1 as a co-receptor for these pathways [2].